We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $936M
1-Year Est. Return 195%
This Fund
S&P 500
This Quarter Est. Return
+25.49%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$4.62B
AUM Growth
-$303M
Cap. Flow
-$719M
Cap. Flow %
-15.57%
Top 10 Hldgs %
43.33%
Holding
116
New
19
Increased
32
Reduced
19
Closed
31

Top Buys

Rank Stock Value
1
UHS icon
Universal Health Services
UHS
+$97.5M
2
SGRY icon
Surgery Partners
SGRY
+$75.3M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$60M
4
PRTA icon
Prothena Corp
PRTA
+$57.7M
5
ARGX icon
argenx
ARGX
+$49.8M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$280M
2
BIIB icon
Biogen
BIIB
+$160M
3
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$120M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$104M
5
HUM icon
Humana
HUM
+$103M

Sector Composition

Rank Sector Weight
1 Healthcare 92.28%
2 Financials 0.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALT icon
26
Altimmune
ALT
$576M
$65.6M 1.42%
3,990,000
+1,306,000
+49% +$14.7M
RVMD icon
27
Revolution Medicines
RVMD
$40B
$59M 1.28%
2,475,000
+153,800
+7% +$3.27M
KRTX
28
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$58.8M 1.27%
299,000
-132,800
-31% -$28.5M
ARWR icon
29
Arrowhead Research
ARWR
$12B
$55.8M 1.21%
1,375,000
+119,626
+10% +$3.96M
AXSM icon
30
Axsome Therapeutics
AXSM
$12.3B
$51.7M 1.12%
670,000
-868,600
-56% -$51.9M
VRTX icon
31
Vertex Pharmaceuticals
VRTX
$122B
$49.7M 1.08%
172,000
-340,800
-66% -$104M
LEGN icon
32
Legend Biotech
LEGN
$3.73B
$48.4M 1.05%
+970,000
New +$47M
KZR
33
DELISTED
Kezar Life Sciences
KZR
$47.7M 1.03%
678,240
+136,800
+25% +$10.1M
PLRX icon
34
Pliant Therapeutics
PLRX
$66.9M
$43.3M 0.94%
2,240,400
+259,300
+13% +$5.42M
VTYX
35
DELISTED
Ventyx Biosciences
VTYX
$42.1M 0.91%
+1,285,000
New +$38.1M
ICLR icon
36
Icon
ICLR
$13B
$41.8M 0.9%
+215,000
New +$42.6M
DGX icon
37
Quest Diagnostics
DGX
$25.6B
$40.4M 0.87%
+258,000
New +$37.1M
BIO icon
38
Bio-Rad Laboratories Class A
BIO
$8.47B
$38.8M 0.84%
92,200
-52,600
-36% -$21.2M
BLU
39
DELISTED
BELLUS Health Inc.
BLU
$37.8M 0.82%
4,599,998
+253,298
+6% +$2.36M
THC icon
40
Tenet Healthcare
THC
$21B
$35M 0.76%
+717,300
New +$33.2M
KPTI icon
41
Karyopharm Therapeutics
KPTI
$161M
$32.8M 0.71%
+642,261
New +$44.5M
BNTX icon
42
BioNTech
BNTX
$23B
$32.4M 0.7%
+215,400
New +$33.1M
VERV
43
DELISTED
Verve Therapeutics
VERV
$30.3M 0.66%
1,565,000
+522,294
+50% +$13.8M
RCKT icon
44
Rocket Pharmaceuticals
RCKT
$355M
$29.9M 0.65%
+1,527,087
New +$28.1M
ITCI
45
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$26.7M 0.58%
504,000
-898,500
-64% -$45M
ARQT icon
46
Arcutis Biotherapeutics
ARQT
$3.48B
$26M 0.56%
1,755,000
+960,500
+121% +$16.8M
RXDX
47
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$22.4M 0.49%
+204,000
New +$13.2M
NTLA icon
48
Intellia Therapeutics
NTLA
$1.49B
$22.3M 0.48%
638,200
-360,900
-36% -$17.2M
VIR icon
49
Vir Biotechnology
VIR
$1.48B
$21.5M 0.47%
+850,000
New +$20.8M
PHAT icon
50
Phathom Pharmaceuticals
PHAT
$953M
$21.3M 0.46%
1,900,000
-6,800
-0.4% -$70.1K
1
2
3 4 5

Similar funds

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Private Wealth Asset Management Cedar Rapids, Iowa $935M AUM 17.66% 1-Year Est. Return
LJAC
L.J. Altfest & Co New York $935M AUM 27.19% 1-Year Est. Return
NI
NetEase Inc Hangzhou, China $934M AUM 11.31% 1-Year Est. Return
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
TW
TritonPoint Wealth Chevy Chase, Maryland $934M AUM 23.95% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Avidity Partners Management's Q4 2022 Portfolio in Review

As of Q4 2022, Avidity Partners Management held 116 positions worth $4.62B, down 6.2% from $4.92B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Avidity Partners Management withdrew a net $719M in Q4 2022, closing 31 positions and reducing 19 holdings. Its most notable exit was Biogen, an estimated $160M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 90% a quarter earlier, followed by Financials.

Against the trend, Avidity Partners Management opened a new position in Universal Health Services worth $116M.

  • Avidity Partners Management's largest Q4 2022 buy was Universal Health Services: 825,600 shares worth $116M.
  • Avidity Partners Management added most to Surgery Partners in Q4 2022, an estimated $75.3M increase.
  • Avidity Partners Management's biggest Q4 2022 reduction was Eli Lilly, cutting an estimated $280M.
  • Avidity Partners Management fully exited Biogen in Q4 2022, selling an estimated $160M.
  • Avidity Partners Management's ten largest holdings make up 43% of its $4.62B portfolio in Q4 2022.
  • Avidity Partners Management opened 19 new positions and closed 31 in Q4 2022.
  • Avidity Partners Management's portfolio value fell 6.2% quarter-over-quarter to $4.62B.

Based on Avidity Partners Management's 13F filing for Q4 2022, filed 14 Feb 2023.